{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:06:30Z","timestamp":1788959190116,"version":"build-2803163510"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Treatment delivered before surgery in colorectal cancer now encompasses several clinically distinct strategies rather than one uniform pathway. These include selective neoadjuvant chemotherapy for radiologically high-risk colon cancer, total neoadjuvant therapy (TNT) and response-adapted organ preservation in rectal cancer, immunotherapy for mismatch repair-deficient or microsatellite instability-high (dMMR\/MSI-H) disease, and perioperative or conversion treatment for colorectal liver metastases (CRLM). This Review separates these settings by treatment intent, expected endpoint, likelihood of surgery, and evidence maturity. MMR\/MSI has direct treatment relevance in localized disease; RAS\/BRAF status and primary tumor sidedness mainly inform metastatic and conversion strategies; HER2-directed treatment remains supported principally by advanced-disease data; and circulating tumor DNA (ctDNA), radiomics, and other dynamic tools remain adjunctive or investigational for most preoperative decisions. Quantitative results from pivotal trials are summarized alongside practical decision boundaries, including clinical complete response assessment, watch-and-wait surveillance, CRLM resectability reassessment, and stopping rules. The central message is deliberately cautious: moving treatment earlier is useful only when the clinical scenario, therapeutic aim, evidence level, reassessment plan, and salvage pathway are defined before treatment begins.<\/jats:p>","DOI":"10.3389\/fonc.2026.1894870","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:12:06Z","timestamp":1788955926000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecularly informed preoperative and response-adapted management of colorectal cancer: evidence, decision boundaries, and emerging directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenjing","family":"Hao","sequence":"first","affiliation":[{"name":"Inner Mongolia Medical University","place":["Hohhot, China"]},{"name":"Affiliated Hospital of Inner Mongolia Medical University","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Inner Mongolia Medical University","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidong","family":"Cheng","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Inner Mongolia Medical University","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Hou","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Inner Mongolia Medical University","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41575-023-00841-9","article-title":"Changing epidemiology of colorectal cancer - birth cohort effects and emerging risk factors","volume":"21","author":"Murphy","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01160","article-title":"Management of locally advanced rectal cancer: ASCO guideline","volume":"42","author":"Scott","year":"2024","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2024.11.003","article-title":"Radiation therapy for rectal cancer: An ASTRO clinical practice guideline focused update","volume":"15","author":"Wo","year":"2025","journal-title":"Pract Radiat Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0041","article-title":"Rectal cancer, version 3.2024: Featured updates to the NCCN guidelines","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12639","article-title":"The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update","volume":"45","author":"Wang","year":"2025","journal-title":"Cancer Commun"},{"key":"B7","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2019180114","article-title":"MRI of rectal cancer: Tumor staging, imaging techniques, and management","volume":"39","author":"Horvat","year":"2019","journal-title":"Radiographics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diii.2023.02.002","article-title":"MRI restaging of rectal cancer: The RAC (Response-Anal canal-CRM) analysis joint consensus guidelines of the GRERCAR and GRECCAR groups","volume":"104","author":"Nougaret","year":"2023","journal-title":"Diagn Interv Imaging"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2022.02.002","article-title":"Lateral lymph nodes in rectal cancer: Do we all think the same? A review of multidisciplinary obstacles and treatment recommendations","volume":"21","author":"Sluckin","year":"2022","journal-title":"Clin Colorectal Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.206","article-title":"Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines","volume":"32","author":"Grothey","year":"2021","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01693","article-title":"ANCHOR CRC: Results from a single-arm, phase II study of encorafenib plus binimetinib and cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer","volume":"41","author":"Van Cutsem","year":"2023","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01553-w","article-title":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial","volume":"27","author":"Nakamura","year":"2021","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102363","article-title":"HER2 targeted therapy in colorectal cancer: New horizons","volume":"105","author":"Suwaidan","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"10213","DOI":"10.1038\/s41467-024-53223-3","article-title":"HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01","volume":"15","author":"Siena","year":"2024","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00219-X","article-title":"First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study","volume":"24","author":"Bond","year":"2023","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00046","article-title":"Preoperative chemotherapy for operable colon cancer: Mature results of an international randomized controlled trial","volume":"41","author":"Morton","year":"2023","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01889","article-title":"Neoadjuvant chemotherapy with oxaliplatin and fluoropyrimidine versus upfront surgery for locally advanced colon cancer: the randomized, phase III OPTICAL trial","volume":"42","author":"Hu","year":"2024","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2026.0085","article-title":"Neoadjuvant chemotherapy vs upfront surgery in patients with locally advanced colon cancer: A randomized clinical trial","volume":"161","author":"Jensen","year":"2026","journal-title":"JAMA Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102676","article-title":"Neoadjuvant chemotherapy for early-stage colon cancer","volume":"123","author":"Audisio","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01184-6","article-title":"Preoperative strategies for locally advanced colon cancer","volume":"25","author":"Nair","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae021","article-title":"Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis","volume":"111","author":"Aliseda","year":"2024","journal-title":"Br J Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.109560","article-title":"Neoadjuvant chemotherapy in locally advanced colon cancer: A systematic review with proportional meta-analysis","volume":"51","author":"van den Berg","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision versus preoperative chemoradiotherapy, total mesorectal excision, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomized, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial","volume":"278","author":"Dijkstra","year":"2023","journal-title":"Ann Surg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomized, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.019","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial","volume":"35","author":"Conroy","year":"2024","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01208","article-title":"Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial","volume":"42","author":"Verheij","year":"2024","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50903","article-title":"Organ preservation and survival by clinical response grade in patients with rectal cancer treated with total neoadjuvant therapy: a secondary analysis of the OPRA randomized clinical trial","volume":"7","author":"Thompson","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303269","article-title":"Preoperative treatment of locally advanced rectal cancer","volume":"389","author":"Schrag","year":"2023","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00903","article-title":"Patient-reported outcomes during and after treatment for locally advanced rectal cancer in the PROSPECT trial (Alliance N1048)","volume":"41","author":"Basch","year":"2023","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00308","article-title":"Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO\/ARO\/AIO-12","volume":"37","author":"Fokas","year":"2019","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.006","article-title":"Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO\/ARO\/AIO-12 and OPRA randomized phase II trials","volume":"36","author":"Williams","year":"2025","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.232748","article-title":"MRI predicts residual disease and outcomes in watch-and-wait patients with rectal cancer","volume":"312","author":"Williams","year":"2024","journal-title":"Radiology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cireng.2025.800248","article-title":"Organ preservation in rectal cancer: Clinical basis of the watch-and-wait strategy","volume":"104","author":"Jimenez-Rodriguez","year":"2026","journal-title":"Cir Esp (Engl Ed)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study","volume":"391","author":"van der Valk","year":"2018","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18050763","article-title":"Clinical complete response and organ preservation strategies in rectal cancer: A real-world single-center experience","volume":"18","author":"Encarnacion","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000004206","article-title":"Organ preservation in rectal cancer management: A prospective GRECCAR snapshot study","volume":"69","author":"Noiret","year":"2026","journal-title":"Dis Colon Rectum"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair-deficient tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00943-6","article-title":"Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response","volume":"21","author":"Williams","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathologic responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02274","article-title":"Neoadjuvant single-cycle pembrolizumab for stage I-III MMR-deficient colon cancer: The RESET-C trial","volume":"44","author":"Gogenur","year":"2026","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.07.004","article-title":"Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: a randomized clinical trial","volume":"42","author":"Xiao","year":"2024","journal-title":"Cancer Cell"},{"key":"B50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-024-01762-y","article-title":"Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102926","article-title":"EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases","volume":"136","author":"Bregni","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.09.037","article-title":"Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review","volume":"141","author":"Bolhuis","year":"2020","journal-title":"Eur J Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0518-2","article-title":"Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)","volume":"121","author":"Oki","year":"2019","journal-title":"Br J Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004389","article-title":"Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS\/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial","volume":"21","author":"Wang","year":"2024","journal-title":"PloS Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00174","article-title":"Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: the BECOME randomized controlled trial","volume":"38","author":"Tang","year":"2020","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S1470-2045(19)30798-3","article-title":"Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Bridgewater","year":"2020","journal-title":"Lancet Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v13.i9.1043","article-title":"Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature","volume":"13","author":"Guo","year":"2021","journal-title":"World J Gastrointest Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2017.05.008","article-title":"Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection","volume":"43","author":"Duwe","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01595-2","article-title":"Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial","volume":"404","author":"Adam","year":"2024","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.029","article-title":"Transplantation for metastatic liver disease","volume":"78","author":"Clift","year":"2023","journal-title":"J Hepatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03235-9","article-title":"Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial","volume":"30","author":"Kopetz","year":"2024","journal-title":"Nat Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-086026","article-title":"Targeted therapy in advanced BRAF-mutated colorectal cancer: systematic review and network meta-analysis","volume":"391","author":"Qin","year":"2025","journal-title":"BMJ"},{"key":"B64","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008037","article-title":"Phase 1a dose escalation study of ivonescimab, an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors","volume":"12","author":"Frentzas","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03843-z","article-title":"Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.0503","article-title":"Evaluation of safety of treatment with anti-epidermal growth factor receptor antibody drug conjugate MRG003 in patients with advanced solid tumors: a phase 1 nonrandomized clinical trial","volume":"8","author":"Qiu","year":"2022","journal-title":"JAMA Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02615","article-title":"Using circulating tumor DNA in colorectal cancer: current and evolving practices","volume":"40","author":"Malla","year":"2022","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210230","article-title":"Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in patients undergoing curative-intent resection with or without adjuvant chemotherapy in colorectal cancer: a systematic review and meta-analysis","volume":"24","author":"Chidharla","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.12.006","article-title":"Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy","volume":"36","author":"Mart\u00ednez-Castedo","year":"2025","journal-title":"Ann Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1026216","article-title":"Artificial intelligence with magnetic resonance imaging for prediction of pathologic complete response to neoadjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis","volume":"12","author":"Jia","year":"2022","journal-title":"Front Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i19.2888","article-title":"Radiomics in colorectal cancer patients","volume":"29","author":"Inchingolo","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","article-title":"Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review","volume":"35","author":"Prelaj","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1894870\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:12:07Z","timestamp":1788955927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1894870\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":75,"alternative-id":["10.3389\/fonc.2026.1894870"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1894870","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1894870"}}